Group 1 - The Hong Kong stock market's innovative drug sector is experiencing significant growth, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising by 4.18%, reaching a new historical high [1] - The ETF has a premium rate exceeding 3%, indicating strong buying interest, with a trading volume surpassing 200 million yuan [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has increased by 107.56% year-to-date, outperforming other innovative drug indices [1] Group 2 - WuXi AppTec reported a revenue of 20.799 billion yuan for the first half of the year, reflecting a year-on-year growth of 20.64%, with net profit attributable to shareholders increasing by 95.5% to 8.287 billion yuan [2] - The global pharmaceutical transaction volume reached 456 deals in the first half of the year, with a total upfront payment of 11.8 billion USD and a total transaction value of 130.4 billion USD, showing significant increases in both quantity and value [2] - Transactions involving China contributed nearly 50% of the total transaction value and over 30% of the total number of deals [2]
暴拉！高溢价！港股通创新药ETF（520880）续涨逾4%，再登全市场ETF涨幅第一
Mei Ri Jing Ji Xin Wen·2025-07-30 02:16